Two phase 2a RCTs in 120 patients with macular oedema from retinal vein occlusion: week-24 visual acuity gain with 601 vs ranibizumab was +16.52 vs +17.79 letters in branch (difference -1.27, 95% CI -5.44 to 2.89) and +13.81 vs +16.79 in central occlusion.
RCTn = 120
Zhao et al. Efficacy and safety of anti-VEGF monoclonal antibody 601 for macular oedema in retinal vein occlusion: two phase IIa randomised clinical trials